“Memphis-based Harmonyx has launched a new test that examines the efficacy and side effect risk of medications used to treat acute and chronic pain.
The test is designed to provide individualized details about which medication may be a good genetic match for patients, along with guidance for dosages and potential side-effect risk.
One in three Americans report suffering from chronic pain. With the serious risks and side effects associated with most pain medications, the test can help ensure a prescription isn’t negatively affecting a patient. The test could also help decrease the rate of abuse and overdose of opioids.
Acute pain, which is frequently the result of common conditions such as headaches, sports injuries and surgeries, accounts for more than 70 percent of emergency department visits. More often than not, the treatment is a non-steroidal anti-inflammatory drug. In the U.S., approximately 70 million prescriptions are issued and 30 billion over-the-counter NSAIDs are sold per year. Risk of gastrointestinal bleeding, a common and potentially fatal side effect, has been associated with genetic variance. Knowing a patient’s genotype in cases like these can prevent serious adverse events like GI bleeding, and can ensure safer, more confident prescribing practices.
The test costs $99 and can be completed with a simple and painless swab test that can be accessed at a Harmonyx partner pharmacy. The test examines the effects of eight genes on a patient’s metabolism and efficacy of more than 20 pain medications, ranging from common over-the-counter drugs such as ibuprofen and naproxen to frequently prescribed medications like morphine, methadone, hydrocodone, codeine and oxycodone, among others. Harmonyx provides a state licensed physician to order and review each patient test. Detailed results are returned to the pharmacist and treating physician in as little as 24 hours once the laboratory receives the test.
Harmonyx test can address side effects of pain medication – Memphis Business Journal.